Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 39,727,815
- Total 13F value
- $25,433,377
- Share change
- +17,967,980
- SEC-reported price per share
- $0.64
- Number of holders
- 37
- Value change
- +$11,324,174
- Number of buys
- 15
- Number of sells
- 14
- Shares outstanding
- 6,426,426
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
37
Top holders
10
XLO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
3/4/5
Lead comparable stake: 20%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-6 of 15 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
20%
Coastlands Capital LP
10%
AbbVie Inc.
9%
STEMPOINT CAPITAL LP
8.4%
Frazier Life Sciences Public Fund...
6.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13D/G
13F
Company
|
20%
|
$9,581,667
14,517,678 shares
|
+$2,576,464 | 31 Dec 2025 |
| Coastlands Capital LP |
13D/G
|
10%
|
$3,742,248
5,346,069 shares
|
$0 | 04 Dec 2025 |
| AbbVie Inc. |
13D/G
|
9%
|
$3,304,348
4,347,826 shares
|
$0 | 11 Feb 2025 |
| STEMPOINT CAPITAL LP |
13D/G
|
8.4%
|
$3,979,818
6,030,028 shares
|
+$1,339,818 | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
6.7%
|
$3,086,472
4,676,472 shares
|
-$2,286,600 | 31 Dec 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
71%
|
$3,848,457
4,566,817 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
37
Shares
39,727,815
Rows available
37
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
36
Q4 2025 holders
37
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend